The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
Irene van der Horst-BruinsmaRianne van BentumFrank D VerbraakThomas RathJames T RosenbaumMaria Misterska-SkoraBengt HoepkenOscar Irvin-SellersBrenda VanLunenLars BauerMartin RudwaleitPublished in: RMD open (2021)
There was a significant reduction in the AAU flare rate during 48 weeks of CZP treatment, indicating that CZP is a suitable treatment option for patients with active axSpA and a history of recurrent AAU.